EUPROTEIN has developed and validated the secreted form of the ACE2 protein expressed in mammalian cell.
Angiotensin converting enzyme 2 (ACE2) is an exopeptidase that catalyses the conversion of angiotensin I to the nonapeptide angiotensin, or the conversion of angiotensin II to angiotensin 1-7. ACE2 has direct effects on cardiac function,a and is expressed predominantly in vascular endothelial cells of the heart and the kidneys. ACE2 is not sensitive to the ACE inhibitor drugs used to treat hypertension.
The protein encoded by this gene belongs to the angiotensin-converting enzyme family of dipeptidyl carboxydipeptidases and has considerable homology to human angiotensin 1 converting enzyme. This secreted protein catalyzes the cleavage of angiotensin I into angiotensin 1-9, and angiotensin II into the vasodilator angiotensin 1-7. The organ- and cell-specific expression of this gene suggests that it may play a role in the regulation of cardiovascular and renal function, as well as fertility. In addition, the encoded protein is a functional receptor for the spike glycoprotein of the human coronaviruses SARS and HCoV-NL63.
ACE2 receptors have been shown to be the entry point into human cells for some coronaviruses, including the SARS virus. A number of studies have identified that the entry point is the same for SARS-CoV-2, the virus that causes COVID-19.
EUPROTEIN has developed and validated these secreted form of the ACE2 proteins expressed in mammalian cell. These high-quality proteins might be applied in basic research of ACE2-related cellular proliferation, as well as studies of COVID-19 mechanisms.
If you need help expressing the ACE2 protein or generating antibodies against them, please submit your inquiry.